Hydroxyurea is a medicine used to treat certain types of cancer, like sickle cell anemia. It works by stopping the growth of cancer cells. It's often given as a pill or intravenously, which means through an IV line.
Every report comes from a Lived member, sent anonymously.
Have you tried Hydroxyurea for Sickle Cell Disease?
Hydroxyurea is a prescription medicine taken by mouth that slows the production of new cells, especially in the bone marrow. It is sold under different brand names for different uses, and the products are not interchangeable. For sickle cell anemia, an inherited condition in which red blood cells stiffen into a crescent shape and block small blood vessels, hydroxyurea reduces painful crises and the need for blood transfusions. Droxia capsules are approved for adults, Siklos tablets for adults and children 2 years and older, and Xromi, a liquid, for children from 6 months of age. National expert guidance recommends it for adults who have frequent severe pain crises, pain or anemia that disrupts daily life, or repeated episodes of acute chest syndrome (a dangerous lung complication of sickle cell disease), and suggests offering it to infants, children and teenagers with sickle cell anemia even before symptoms become frequent. Hydrea capsules are approved as a cancer medicine: for chronic myeloid leukemia (CML) that has not responded to other treatment, and, together with chemotherapy and radiation, for some advanced cancers of the head and neck. Hematologists also commonly use hydroxyurea off-label to lower blood counts in polycythemia vera and essential thrombocythemia, bone marrow disorders that make too many red cells or platelets and raise the risk of clots.
Hydroxyurea blocks an enzyme cells need to build DNA. Cells that divide quickly, such as cancer cells and the bone marrow cells that make blood, are affected most, which is why it can shrink an overactive blood cell population and also why it lowers normal blood counts. In sickle cell anemia the benefit seems to come from several effects together. Hydroxyurea raises fetal hemoglobin, a form of hemoglobin made before birth that does not sickle, so red cells containing it are less likely to change shape. It also lowers the number of white blood cells and makes red cells more flexible and less sticky against blood vessel walls. Fetal hemoglobin usually starts rising 4 to 12 weeks after treatment begins, but researchers have not shown that this rise alone explains why crises become less frequent.
Hydroxyurea is usually taken once a day, at about the same time each day. The dose is based on body weight and adjusted according to blood test results, so it differs from person to person and changes over time. For sickle cell anemia, treatment starts at a lower dose and is raised gradually every few weeks while blood counts stay in a safe range, with blood tests about every 2 weeks during adjustment. Cancer treatment with Hydrea calls for blood counts at least weekly. People with reduced kidney function generally need a lower dose. Capsules should be swallowed whole and never opened, broken or chewed, because the powder is toxic to healthy cells. Siklos tablets are scored so they can be split, and they can be dispersed in a small amount of water just before taking for someone who cannot swallow them. Anyone who handles the medicine for another person should wear disposable gloves and wash their hands before and after. Prescribers often recommend a daily folic acid supplement alongside it.
Lower blood counts are the most important and most expected effect, which is why regular testing is built into treatment. Other common effects include nausea, poor appetite, diarrhea or constipation, mouth sores, thinning hair, darkening of the nails or skin, and dry or scaly skin. Hydroxyurea also enlarges red blood cells; this is expected and not harmful in itself, but it can hide a vitamin B12 deficiency on routine tests. Because white cells and platelets can drop, contact the care team right away about a fever, chills or other signs of infection, and about unusual bleeding or bruising. Also seek prompt medical advice for a new cough, fever or shortness of breath, since hydroxyurea can rarely inflame the lungs. Painful skin ulcers, especially on the legs, should be reported, as they may need a dose change or a pause in treatment. Low counts usually recover within about two weeks once the dose is paused.
The Droxia and Siklos labels carry the FDA's most prominent warning, a boxed warning, about two risks that apply to all hydroxyurea. It can lower blood counts severely, so it is not started when the bone marrow is already weak and blood tests continue for as long as it is taken. It can also cause cancer: leukemia and skin cancers have been reported with long-term use, so people are monitored over the long term and advised to protect their skin from the sun. For many people with sickle cell anemia, specialists judge that the benefit of fewer crises and complications outweighs this long-term risk, which is worth discussing openly. Hydroxyurea can harm a developing baby. Women who could become pregnant should use effective birth control during treatment and for at least 6 months after stopping, and men with a partner who could become pregnant should use it for at least a year after. Anyone who becomes pregnant should tell the prescriber right away. Breastfeeding is not recommended during treatment. Hydroxyurea can reduce sperm counts, sometimes permanently, so men may want to ask about sperm banking before starting. Live vaccines, which contain a weakened form of the germ, should be avoided because they can cause serious infection, so check with the care team before any vaccination. Hydroxyurea can make some continuous glucose monitors read falsely high, which could lead to low blood sugar if insulin is dosed from those readings, so people with diabetes should tell both prescribers. In people with HIV, taking it with the older antiretroviral medicines didanosine and stavudine has caused fatal pancreatitis and liver failure.
For sickle cell anemia, hydroxyurea is a long-term preventive treatment, not a rescue medicine for a crisis that has already started. Finding the right dose usually takes several months of gradual increases and frequent blood tests. In the main adult study, people taking it had roughly half as many painful crises as those on placebo, along with fewer hospital stays, fewer episodes of acute chest syndrome and fewer transfusions. The benefit depends on taking it every day. Once the dose is stable, blood tests become less frequent but continue for as long as treatment lasts, and the care team may also track fetal hemoglobin to see how well it is working. In cancer and bone marrow disorders, the dose is guided by how blood counts and the disease respond. Long-term follow-up, skin checks and sun protection remain part of care for anyone on hydroxyurea for years.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Hydroxyurea, what you've noticed, or ask the community a question.